Chronic Myeloid Leukemia Stem Cell Therapy Development

Stem cell therapy is a promising approach for the treatment of chronic myeloid leukemia (CML), a type of blood cancer. The therapy involves the use of stem cells, which are undifferentiated cells that have the ability to develop into different types of cells in the body. CD BioSciences provides stem cell therapy development services for our global customers for assisting them making better breakthrough in the therapeutic development of CML.

Introduction into Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is a slow-growing cancer that develops in the myeloid cells, which are responsible for producing red blood cells, white blood cells, and platelets. CML is caused by genetic mutation that results in the production of an abnormal protein called BCR-ABL, which causes the myeloid cells to grow and divide uncontrollably. This leads to the accumulation of immature white blood cells, known as blast cells, in the bone marrow and blood. The symptoms of CML can vary from person to person, but they often include fatigue, weakness, fever, weight loss, and night sweats. In some cases, CML may not cause any symptoms and may only be detected through routine blood tests.

The anatomy of the bone marrow microenvironment of CML (stem) cells (Minciacchi, et al., 2021)

Stem Cell Therapy for Chronic Myeloid Leukemia

The procedure for stem cell therapy in CML involves harvesting healthy stem cells from the patient or a donor, then transplanting them into the patient's body. This can be done through a bone marrow transplant, where the healthy stem cells are taken from the bone marrow, or through a peripheral blood stem cell transplant, where the healthy stem cells are taken from the blood. After the transplant, the healthy stem cells will migrate to the bone marrow and start producing new blood cells, replacing the abnormal cells that were causing CML. The success of the treatment depends on various factors, including the age and overall health of the patient, the type of transplant, and the level of compatibility between the donor and recipient.

There are basically two types of stem cell transplantation for CML:

Autologous transplant: the patient's own stem cells are collected from the blood or bone marrow and then returned after treatment. The problem is that leukemia cells may be collected along with the stem cells.

Allogeneic transplant: the stem cells come from another individual (the donor). To reduce the chance of complications, the donor needs to be "matched" to the patient's tissue type. Usually, a close relative, such as a brother or sister, is a good match. Less commonly, a match may be found for an unrelated donor.

While stem cell therapy can be an effective treatment for CML, it is a complex and risky procedure that requires careful monitoring and follow-up care.

Our Services

CD BioSciences offers stem cell therapy development service for CML. Based on our professional laboratory team, advanced technology and years of experiences.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Minciacchi, Valentina R et al. "Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future." Cells vol. 10,1 117. 10 Jan. 2021.